The Basics of Large-Scale Commercial Production of Monoclonal Antibodies

Commercial production of monoclonal antibodies is a pivotal aspect of modern biotechnology industries. Monoclonal antibodies used to be generated by fusing a specific B cell with a myeloma cell to form a hybridoma to produce antibody. Later, the production of monoclonal antibodies utilizing animal cell lines like CHO and HEK293 became cornerstone of biopharmaceutical manufacturing. This process involves animal cell culture in bioreactors under optimized conditions to produce monoclonal antibodies. Antibody-producing stable cell line is generated through transfection and selection processes. These engineered cell lines are then expanded in culture, with medium formulations tailored to support cell growth and antibody production. Bioreactor parameters are carefully controlled to maximize cell productivity. Harvested cell culture supernatants are subsequently purified using chromatography techniques to isolate the antibody. Commercial monoclonal antibody production using animal cell lines enables scalable and efficient manufacturing of therapeutic antibodies for various clinical applications, contributing significantly to the biopharmaceutical industry.